143 related articles for article (PubMed ID: 32742481)
1. Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study.
Huang Q; Chu C; Tang J; Dai Z
J Cancer; 2020; 11(18):5353-5358. PubMed ID: 32742481
[No Abstract] [Full Text] [Related]
2. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
4. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W; Li Z; Zheng Z; Wu X
Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
[TBL] [Abstract][Full Text] [Related]
6. Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.
Zhang J; Li A; Jiang Q; Zheng F; Zhu H
Drug Des Devel Ther; 2019; 13():3913-3918. PubMed ID: 31814710
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
Yang H; Geng A; Wang Z; Wu C
J Obstet Gynaecol Res; 2023 Jun; 49(6):1611-1619. PubMed ID: 36988159
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study.
Sun F; Lu S; Zhen Z; Zhu J; Wang J; Huang J; Zhang Y; Li H; Cai R; Liu M; Wu L; Sun X; Zhang Y
Cancer Manag Res; 2020; 12():6177-6185. PubMed ID: 32801866
[TBL] [Abstract][Full Text] [Related]
10. Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial.
He Z; Zhou H; Wang J; Li D; Zhang X; Wang P; Ma T; Zhang Y; Tian C; Chen Y; Zou M; Han Y; Xu C; Ma S; Wang L; Wu X; Chen G; Wang Q
Transl Lung Cancer Res; 2021 Feb; 10(2):889-899. PubMed ID: 33718030
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial.
Hou Z; Lan C; Huang X; Salcedo-Hernández RA; El-Tawab S
Transl Cancer Res; 2023 Oct; 12(10):2959-2967. PubMed ID: 37969395
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.
Yu J; Xu Z; Li A; Zhang J; Wang Y; Zhao H; Zhu H
Drug Des Devel Ther; 2019; 13():3419-3424. PubMed ID: 31576114
[TBL] [Abstract][Full Text] [Related]
13. A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.
Hu N; Zhu A; Si Y; Yue J; Wang X; Wang J; Ma F; Xu B; Yuan P
Front Oncol; 2020; 10():565384. PubMed ID: 33659204
[TBL] [Abstract][Full Text] [Related]
14. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
15. A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients.
Yang M; Liu X; Zhang C; Liao F; Li Z; Luo X; Sun Y; Chen C
Cancer Manag Res; 2019; 11():8869-8876. PubMed ID: 31632146
[TBL] [Abstract][Full Text] [Related]
16. Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy.
Tao CJ; Zhang P; Zhou L; Hu QY; Chen XZ
Transl Cancer Res; 2020 Oct; 9(10):6392-6401. PubMed ID: 35117247
[TBL] [Abstract][Full Text] [Related]
17. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
18. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
[TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of apatinib mesylate for the treatment of multi-drug resistant advanced breast cancer].
Lü HM; Zhang MW; Niu LM; Zeng HA; Yan M
Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1246-1249. PubMed ID: 29747313
[No Abstract] [Full Text] [Related]
20. Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option.
Zhang HH; Du XJ; Deng ML; Zheng L; Yao DC; Wang ZQ; Yang QY; Wu SX
Front Pharmacol; 2022; 13():969565. PubMed ID: 36060005
[No Abstract] [Full Text] [Related]
[Next] [New Search]